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Translational Relevance. 
Our study has shown that cytokine-Induced killer lymphocytes (CIK) engineered with a CSPG4-CAR are 
effective in eliminating many types of soft tissue sarcoma (STS)-derived cells both in vitro and in immune 
deficient mice. These pre-clinical results provide a strong rationale for the clinical translation of the CSPG4-
CAR.CIK-based immunotherapeutic strategy we have developed. Patients with unresectable high-grade STS 
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No effective therapy is available for unresectable soft tissue sarcomas (STS). This unmet clinical need has 
prompted us to test whether chondroitin sulfate proteoglycan 4 (CSPG4)-specific CAR-redirected cytokine-
induced killer lymphocytes (CAR.CIK) are effective in eliminating tumor cells derived from multiple STS 
histotypes in vitro and in immunodeficient mice.  
Experimental Design.  
The experimental platform included patient-derived CAR.CIK and cell lines established from multiple STS 
histotypes. CAR.CIK were transduced with a retroviral vector encoding 2nd-generation CSPG4-specific CAR 
(CSPG4-CAR) with 4-1BB co-stimulation. The functional activity of CSPG4-CAR.CIK was explored in vitro, in 2D 
and 3D STS cultures, and in three in vivo STS xenograft models. 
Results.  
CSPG4-CAR.CIK were efficiently generated from STS patients. CSPG4 was highly expressed in multiple STS 
histotypes by in silico analysis and on all the 16 STS cell lines tested by flow cytometry. CSPG4-CAR.CIK 
displayed superior in vitro cytolytic activity against multiple STS histotypes as compared to paired unmodified 
control CIK. CSPG4-CAR.CIK also showed strong anti-tumor activity against STS spheroids; this effect was 
associated with tumor recruitment, infiltration, and matrix penetration. CSPG4-CAR.CIK significantly delayed 
or reversed tumor growth in vivo in three STS xenograft models (Leiomyosarcoma, UPS and Fibrosarcoma). 
Tumor growth inhibition persisted for up to 2 weeks following the last administration of CSPG4-CAR.CIK. 
Conclusions.  
This study has shown that CSPG4-specific CAR-redirected CIK effectively target multiple STS histotypes in vitro 
and in immunodeficient mice. These results provide a strong rationale to translate the novel strategy we 
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Soft tissue sarcomas (STS) are rare tumors of mesenchymal origin that affect both children and adults (1). 
These peculiar tumors encompasses multiple histotypes, which are characterized by extremely variable 
biological and clinical behaviours. Chemotherapy and molecularly targeted approaches may offer transient 
disease control to patients non-eligible for radical surgical resection. However, the overall prognosis remains 
dismal with a 5-year survival rate of less than 25% (1-3). STS are also poorly responsive to checkpoint 
blockade-based immunotherapy (3-6). This unmet clinical need has prompted us to develop a novel strategy 
for the treatment of multiple STS histotypes (7).  
Adoptive immunotherapy with T lymphocytes redirected by tumor antigen (TA)-specific chimeric antigen 
receptors (CAR) is one of the most effective therapy in B-cell malignancies (8-10). However, application of 
CAR.T cells to solid tumors remains challenging (11-15). Here, we have tested the ability of cytokine-induced-
killer T-lymphocytes (CIK) engineered with a TA-specific CAR to target tumor cells obtained by multiple STS 
hystotypes in vitro and in vivo. CIK are patient-derived polyclonal T-NK lymphocytes endowed with HLA class 
I-independent antitumor activity, mediated mostly by the interaction of their NKG2D receptor with stress-
inducible targets (MIC A/B; ULBPs 1-6) on tumor cells (16-26). To increase their tumor cell specificity, CIK 
were engineered with a TA-specific CAR. CAR engineered CIK have been modeled in hematological 
malignancies to target either CD19 or CD33/CD23 antigens (27-31), and clinical trials are currently ongoing. 
We and others studied the use of CAR expressing CIK in STS (32-35). In our previous study, we demonstrated 
the preclinical effectiveness of CAR-redirected CIK against CD44v6, which is expressed in about 40% of STS 
(32). Here we assessed whether alternative TA could be targeted via CAR engineered immune cells in STS to 
further expand their clinical applicability. 
The TA chondroitin sulfate proteoglycan 4 (CSPG4), a cell surface proteoglycan that plays an important role 
in oncogenic pathways involved in cancer progression and metastatic spread (36-42), was selected as the 
target for the following reasons. CSPG4 is highly expressed with limited heterogeneity on both differentiated 
cancer cells and cancer initiating cells (CICs) in several types of cancer. According to the cancer stem cell 
hypothesis, CICs play a major role in disease recurrence and metastatic spread, the two major causes of 
patients’ mortality and morbidity. In contrast, CSPG4 is not detectable in normal tissues. Furthermore, CSPG4 
is expressed by activated pericytes in the tumor microenvironment (43). As a result, CSPG4 immuno-targeting 
selectively inhibits neoangiogenesis in the tumor microenvironment, thus contributing to the elimination of 
the vasculature that supports tumor growth (44). 
This manuscript describes the in vitro and in vivo ability of CSPG4-CAR.CIK to eliminate STS cells following a 
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Materials and Methods 
Data analysis of CSPG4 RNA expression in The Cancer Genome Atlas 
RNA-sequencing expression data were selected and downloaded from the cBioPortal, TCGA PanCancer 
collections (45,46). The dataset included 251 STS samples: Leiomyosarcoma n=99, Dedifferentiated 
Liposarcoma n=58, UPS/Malignant Fibrous Histiocytoma/High-Grade Spindle Cell Sarcoma n=50, 
Myxofibrosarcoma n=25, Malignant Peripheral Nerve Sheath Tumor (MPNST) n=9, and Synovial Sarcoma 
n=10. Another 336 melanomas served as a positive expression control and various epithelial tumors (Breast 
Cancer n=1082, Pancreatic Cancer n=176, Lung Adenocarcinoma n=510, Lung Squamous Cell Carcinoma 
n=482) were explored for comparison. RSEM expression values were plotted after Log2 transformation with 
0.5 jittering on the x-axis using Microsoft Excel®. 
 
Soft Tissue Sarcoma (STS) cell lines and STS spheroids 
STS cell lines were generated in our laboratory from patient-derived surgical biopsies (47). We received 
approval for collection of patient samples and the associated informed consent document from the 
Institutional Review Board (IRB) per Declaration of Helsinki guidelines (Prot. Number 225/2015); each patient 
signed an informed consent. Patient-derived STS were cultured in either KO DMEM F12 (KO Out Dulbecco’s 
Modified Eagle Medium, Gibco BRL) or IMDM (Iscove’s Modified Dulbecco Medium, Sigma Aldrich) medium, 
with 10% or 15% FBS, 25 mmol/L HEPES, 100 U/mL penicillin, and 100 U/mL streptomycin (Gibco BRL) in a 
humidified 5% CO2 incubator at 37°C. Patient-derived melanoma cell line M14 (48), which does not express 
CSPG4, was used as a specificity control and cultured in RPMI 1640 medium (Sigma Aldrich ), supplemented 
with 10% heat inactivated FBS, 100 U/mL penicillin, and 100 U/ mL streptomycin (Gibco BRL) at 37°C in a 5% 
CO2 incubator.  The HT1080 cell line used in this study was originally obtained from the American Type Culture 
Collection (ATCC), and was authenticated by genotype analysis with the Cell ID system (Promega) that 
compared their profile with those published on the DMSZ database. Adult and neonatal keratinocytes were 
cultured with the Lonza KGM™ Gold Keratinocyte Growth Medium Bullet Kit™. 
Three-dimensional STS spheroids were generated as a single spheroid per well using ultra-low attachment 
(ULA) 96-well round bottom plates (Corning) with no additional coating.  A STS cell suspension of between 
500 and 5000 cells/100 μl was plated into wells and then centrifuged at 1000 g for 10 min (33). STS spheroids 
were assembled in 1-4 days, depending on the target histotypes. We generated GFP+ STS spheroids from cells 
previously transduced with the pRRL.sin.PPT.hOct4.eGFP.Wpre VSV-G pseudo-typed third-generation 
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Generation of CSPG4-CAR.CIK  
Supernatants containing retroviral particles encoding CAR specific for the CSPG4 antigen (CSPG4-CAR) or the 
control vector encoding CAR specific for the CD19 antigen (CD19-CAR), both containing 4-1BB costimulatory 
endodomains were generated as previously described (41). We generated CSPG4-CAR.CIK and CSPG4-CAR.T 
cells from peripheral blood mononuclear cells (PBMC) isolated from patients diagnosed with STS by density 
gradient centrifugation using Lymphosep (Aurogene). Approval was obtained from the IRB per the 
Declaration of Helsinki guidelines for the collection of biological samples (tumors and blood) and for patient 
informed consent releases (Prot. Number 225/2015). For CAR.CIK, PBMC from 8 patients with STS (Suppl. 
Table 1) were seeded on day 0 in cell culture flasks at a concentration of 2 x 106 cells/mL with IFNγ (Miltenyi 
Biotec; 1000 U/mL) in RPMI-1640 medium (Gibco BRL), 10% FBS (Sigma), 100 U/mL penicillin, and 100 U/mL 
streptomycin (Gibco BRL). Following a 24 hour incubation at 37°C, PBMC were activated by Anti-Biotin 
MACSiBead Particles loaded with anti-CD2, -CD3, and -CD28 mAbs (Miltenyi Biotec) and human interleukin 
(IL)-2 IS (Miltenyi Biotec, 300 U/mL). To generate CAR.T cells, PBMC were seeded on day 0 at a concentration 
of 2 x 106 cells/mL and activated using Anti-Biotin MACSiBead Particles. On day +1, human interleukin (IL)-2 
IS (Miltenyi Biotec, 50 U/mL) was added. On day +2, PBMC were transduced with 0.5 ml of retroviral 
supernatants in retroNectin™-coated plates by overnight incubation. Unmodified NTD.CIK and NTD.T cells 
were used as a paired control. Both CAR.CIK and control NTD.CIK were expanded over 4 weeks, refreshed 
with IL-2 medium (CIK: 300 U/mL) every 2–3 days as needed, and cultured at 1.8 x 106 cells/mL. CAR.T cells 
were cultured at 1.8 x 106 cells/mL for 1 week, and the IL-2 (50 U/mL) medium was refreshed every 2–3 days 
as needed. 
 
Flow cytometry  
Conjugated CD3, CD4, CD8, CD56, PD-1, CXCR3, CXCR4, and CCR7 mAbs (BD Pharmingen) and CD45RO, 
CD45RA, and CD62L mAbs (Miltenyi Biotec) were used to characterize lymphocytes.  A mAb specific for the 
IgG1/CH2CH3 spacer (Jackson ImmunoResearch) was used to detect CAR expression. STS cells were stained 
with conjugated mAbs for the expression of CIK NKG2D ligands MIC A/B (BD Pharmingen) and ULBPs (R&D 
Systems), and for the expression of HLA-ABC, PD-L1 and PD-L2 (BD Pharmingen). STS were stained for CSPG4 
with mAbs 225.28, 763.74, and D2.8.5-C4B8 (49), which  recognize distinct and spatially-distant epitopes of 
CSPG4. Cells were incubated first with CSPG4-specific mAbs (1 μg/mL for all mAbs), then washed and 
incubated with rabbit anti-mouse IgG-PE secondary antibody (Miltenyi Biotec). Alternatively, CSPG4 was 
detected with the conjugated anti-human CSPG4-APC mAb (Miltenyi Biotec). CSPG4 molecules expressed on 
the surface of STS and other cell lines were measured using a quantitative immunofluorescence assay (Bangs 
Laboratories, Inc.). Briefly, cells of interest and calibration beads with increasing amounts of antibody capture 
Cancer Research. 
on September 30, 2020. © 2020 American Association forclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on September 8, 2020; DOI: 10.1158/1078-0432.CCR-20-0357 
7 
 
capability were labeled simultaneously with the anti-human CSPG4-APC mAb. Labeled cells and calibration 
beads were analysed, and a standard regression line was calculated between fluorescence intensity and 
antigen density, expressed as Ab-binding capacity (ABC) in molecules per cell. We defined high CSPG4 
expression as 2-fold increase as compared to normal keratinocytes. Labeled cells were acquired on FACS Cyan 
(Cyan ADP, Beckman Coulter s.r.l.) and analyzed using Summit Software. 
 
Tumor cell killing assays 
We assessed the tumor-killing ability of patient-derived CSPG4-CAR.CIK and unmodified NTD.CIK in vitro 
against STS cell monolayers and STS 3D spheroids. In two cases, CIK and STS cell cultures were generated 
from samples collected from the same patient (S1 and S172), while in all other cases cytotoxicity assays were 
performed with HLA mismatched effector cells. Cytotoxicity assays against STS cell monolayers were 
performed using flow cytometry or a bioluminescent cell viability assay. In the first case, target cells were 
stained with either vital dye PKH26 (Sigma-Aldrich) or CFSE (5,6-carboxyfluorescein diacetate succinimidyl 
ester; Molecular Probes), according to the manufacturer’s protocols. Immune-mediated killing was analyzed 
by flow cytometry (Cyan ADP, Dako) and measured by the DAPI permeability of target cells (PKH26+ or CFSE+ 
gate). For the bioluminescent method, cytotoxicity was measured with the CellTiter-Glo®Luminescent Cell 
Viability Assay (Promega), in which the number of viable and metabolically active target cells is evaluated by 
quantifying the ATP in culture. CIK cells were co-cultured at different effector to target cell ratios (10:1, 5:1, 
2.5:1, 1:1, 1:2, and 1:4) in cytotoxicity assays (300 U/mL IL-2 medium at 37°C and 5% CO2) for 5 hours (short-
term assay) and 48 hours (long-term assay). In selected experiments, we tested the cytotoxic activity at very 
low effector to target cell ratios (1:8, 1:16, 1:32, and 1:64). Target cells were also tested separately from CIK 
cells as a control to assess their spontaneous mortality. The percentage of STS specific lysis for each effector 
to target cell ratio was calculated using the following formula: [(experimental−spontaneous 
mortality/100−spontaneous mortality) × 100]. In selected experiments, growth of residual sarcoma cells was 
investigated 48 hours after the treatment with either CSPG4-CAR.CIK or NTD.CIK. 
In 3D assays, STS spheroids stably expressing GFP were seeded one per well in ULA 96-well round bottom 
plates. CSPG4-CAR.CIK and unmodified NTD.CIK were stained with PKH26 dye and plated at E:T ratio 2:1 in 
culture medium with 300 U/mL IL-2 at 37°C, 5% CO2. Fluorescence images were acquired at 12 hour intervals 
over 96 hours under the same magnification (10x). Killing activity was determined as loss of GFP fluorescent 
spheroid area (pixel) using fluorescent microscopy (Leica DMI 3000B equipped with Photometrics CoolSnap 
HQ CCD camera). Untreated STS spheroids were used to evaluate spontaneous mortality. All images were 
analysed with ImageJ software, and percentage of tumor cell lysis was determined by the formula: [100 - 
(treated GFP+ STS spheroid (pixel) x 100 / untreated GFP+ STS spheroid (pixel)]. 
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Immunofluorescence analysis of CSPG4-CAR.CIK cell recruitment and infiltration in STS spheroids 
GFP+ STS spheroids were co-cultured with CSPG4-CAR.CIK or unmodified NTD.CIK cells stained with red dye 
PKH26 at E:T ratio 2:1 in culture medium (300 U/mL IL-2 at 37°C, 5% CO2). Following a 16 hour co-culture at 
37°C, CIK cells were removed and immunofluorescence acquisition was conducted on the remaining 
spheroids. Briefly, STS spheroids were washed twice, and then centrifuged at 300 g for 3 min in PBS, fixed in 
paraformaldehyde 4% for 1 hour, resuspended with mounting medium, and applied on either glass slides or 
glass bottom chamber slide wells. STS spheroids were observed using a Leica SP8 AOBS confocal microscope. 
Next, 80MHz pulsed white light laser (470-670 nm) was used to excite the fluorochromes in the spheroids. 
Fluorescence channels were scanned sequentially, and hybrid spectral detectors (HyD SP Leica Microsystems) 
revealed the emissions. Image acquisition of the STS spheroids was performed maintaining the same laser 
power, gain, offset, and magnification (20x). We generated maximum intensity projections for each analysed 
spheroid with LAS X software (Leica) to quantify CIK cell recruitment and infiltration. Images of the total 
PKH26 red fluorescent area (μm2) present either at the boundary or inside the spheroid were analysed using 
ImageJ software. 
 
CIK cell penetration capability into Matrigel® matrix  
STS spheroids were collected, washed in PBS, resuspended in 20 μl of liquefied Matrigel® (BD Pharmingen) 
at 4°C, and then plated as droplets in well centres of a 24-well tissue culture plate that had been pre-warmed 
to 37°C. Plates were incubated at 37°C and 5% CO2 for 15 min to allow the solidification of the Matrigel® 
domes. Domes were then overlaid with 500 μl of pre-warmed medium with 300 U/mL IL-2 and co-cultured 
with PKH2-stained CSPG4-CAR.CIK or unmodified NTD.CIK cells (50.000 cells/well) for 5 days. Empty domes 
were used as controls. At the end of the co-culture period, each well was washed twice with pre-warmed 
PBS to eliminate any effector cells outside the domes. Fluorescence microscopy (Leica DMI 3000B with 
Photometrics CoolSnap HQ equipped with CCD camera) was used to visualise CSPG4-CAR.CIK or unmodified 
NTD.CIK cell migration at the Matrigel® boundary and cells that penetrated into the Matrigel® domes.  
Analysis of the PKH26 red fluorescent dye presence (μm2) was performed with ImageJ software.   
 
In vitro cytokine production 
CSPG4-CAR.CIK and CSPG4-CAR.T cells, unmanipulated NTD.CIK and NTD.T cells were co-cultured alone or 
with tumor cells in RPMI 1640 medium with 300U/ml (CIK) or 50U/ml IL-2 (T cells) at a 2:1 effector-to-target 
ratio and incubated at 37°C for 48 hours. Concentrations of cytokines in culture supernatant were measured 
using the Bio-Plex Pro™ Human Cytokine 9-plex Assay kit (Bio-Rad Laboratories Inc.) according to the 
manufacturer's directions. Each sample was measured in duplicate. Data were acquired and analysed by 
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Bioclarma (Analysis Service). Granzyme B concentration was measured in supernatants from mixed 
target/effector cell cultures (ELISA Granzyme B kit; Diaclone SAS, Besancon, France), as recommended by the 
manufacturer. 
 
In vivo activity of patient-derived CSPG4-CAR.CIK 
The antitumor activity of CSPG4-CAR.CIK and unmodified NTD.CIK was evaluated using STS xenograft models 
in immunodeficient mice. In vivo experiments received approval by the competent committee and internal 
review board (Auth. Number 178/2015-PR). STS xenografts were established in seven- to eight-week-old 
NOG/SCID/γc_/_ (NSG) or NOD/SCID (Charles River Laboratories, SRL, Italy) female mice by subcutaneous 
injection with 1x106 cells obtained from three STS [fibrosarcoma (HT1080), leiomyosarcoma (S172), UPS (S1)].  
Autologous CSPG4-CAR.CIK and unmodified NTD.CIK were available for S172 and S1 xenografts. Allogeneic 
CSPG4-CAR.CIK from unrelated STS patients were generated following the same protocol used to generate 
autologous CIK identical and used in the HT1080 xenograft model. When tumors were approximatively 50 
mm3, mice were infused twice a week with 1x106 CSPG4-CAR.CIK or unmodified NTD.CIK resuspended in PBS 
(200 µL), for a total of four infusions. Mice injected with PBS only were used as controls. Treatment and 
control cohorts included 6 mice each for the leiomyosarcoma (S172) group. For the fibrosarcoma (HT1080) 
and UPS (S1) xenografts and control groups, each group included 3 mice. In the experiments with 
fibrosarcoma (HT1080) and leiomyosarcoma (S172), mice were sacrificed at the end of treatment. In the 
experiment with UPS (S1), mice were sacrificed 14 days after the last CIK infusion. Mice were monitored daily 
for possible toxicities, while tumor growth was measured weekly with manual caliper. Mice were sacrificed 
at the end of treatment or if tumor reached 2 cm along the main diameter. In additional experiments mice 
engrafted with the S172 cell line (n = 4 mice per treatment) or the HT1080 cell line (n = 5 mice per treatment) 
were infused with CSPG4-CAR.CIK and unmodified NTD.CIK generated from unrelated donors. In these 
models, when the tumor volume was approximatively 20 mm3, mice received two infusions (on day 0 and 
day +4) of 3x106 CSPG4-CAR.CIK or unmodified NTD.CIK. Mice were sacrificed 11 days after the last dose of 
cells. Tumor volume was calculated by the following formula: V= 4/3 x π x (a/2)2 x (b/2), where a is the length 
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STS xenografts were analysed by IHC to assess CSPG4 expression. Samples (5-μm thick) were cut from 
formalin-fixed paraffin-embedded (FFPE) tissue sections, mounted on slides, and treated as per standard 
immunohistochemistry procedures. Tissue sections were deparaffinised with 100% xylene and rehydrated 
with decreasing concentrations of ethyl alcohol. Antigen retrieval was performed by boiling the sections in 1 
mM EDTA (pH 9.0) for 60 min. Slides were treated with 3% hydrogen peroxide, 1% bovine serum albumin 
(BSA) (Invitrogen), and 5% normal horse serum in Tris-buffered saline (25 mM Tris [pH 7.4], 150 mM NaCl) 
containing 0.1% Tween 20 (Sigma-Aldrich, Inc). Slides were then incubated in a closed humid chamber 
overnight at 4°C with the CSPG4-specific mAb 225.28, 763.74, and D2.8.5-C4B8 (4 μg/ml each) pool. After 
washing, a secondary anti-mouse IgG xenoantibody was added. Secondary antibodies conjugated to HRP 
were generated and IHC signals were detected with the EnVision1® System-HRP (Dako North America, Inc) 
and chromogen diaminobenzidine (DAB) substrate (DakoCytomation Liquid DAB+ Substrate Chromogen 
System, Dako). Tissue sections were counterstained with Mayer Haematoxylin (Bio-Optica). We also explored 
the presence of infiltrated CSPG4-CAR.CIK, unmodified NTD.CIK cells and apoptotic tumor cells in explanted 
tumors from treated mice. Tissues were stained according to the manufacturer’s protocols with the primary 
polyclonal antibody anti-CD3 (DAKO) and anti-cleaved caspase 3 (Cell Signalling). Tissue sections were 
mounted on glass slides and visualized with a DM750 Leica microscope equipped with Leica ICC50W CCD 
camera (LAS EZ3.4.0 software).  
 
Statistical analysis 
All experiments were performed at least twice. Data were analyzed using GraphPad Prism 8.0 (GraphPad 
Software, La Jolla, CA). Descriptive data are presented as mean values ± standard errors. To find statistical 
significance in the comparison of two groups, we used two-tailed Student’s t-tests; for comparison of three 
or more groups, the data were analyzed by two-way ANOVA with Bonferroni’s multiple comparison post-
tests.  A p-value < 0.05 was considered significant. Significance is represented on graphs as *P ≤ 0.05, **P ≤ 
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Generation and characterization of patient-derived CSPG4-CAR.CIK. 
CIK cells were efficiently generated from peripheral blood mononuclear cells (PBMCs) collected from eight 
patients diagnosed with STS. We genetically engineered CIK to express the CSPG4-CAR that includes the 4-
1BB costimulatory endodomain. Three weeks following transduction and ex vivo expansion, the mean 
expression of CAR on engineered CIK (CSPG4-CAR.CIK) was 48% ±6 as assessed by flow cytometry (Suppl. 
Table 1 and in Suppl. Fig 1A) and was comparable to that obtained using the retroviral vector encoding the 
CD19-specific CAR (CD19-CAR). Ex vivo expansion of CSPG4-CAR.CIK was 154-fold (27-348) and was 
comparable to that observed with paired control unmodified CIK (NTD.CIK). The phenotypic characterization 
of CSPG4-CAR.CIK was comparable to that of paired unmodified NTD.CIK showing CD8+ cells as the main 
cellular subset (69% ±4) of which 39% ±5 of them co-expressed the CD56 molecule (CD3+CD56+) (Suppl. Table 
1). The NKG2D receptor was 66% ±5, and 47% ±0.1 of the cells were CD62L+CD45RA-, the latter represent the 
effector-memory-like population (Suppl. Fig. 1B). The immune-checkpoint receptor PD-1 was expressed on 
12% ±2 in both CSPG4-CAR.CIK and NTD.CIK (Suppl. Table 1).  
CSPG4 as a potential CAR target in STS. 
We confirmed first that CSPG4 is expressed in multiple STS histotype cells (Leiomyosarcoma; Dedifferentiated 
Liposarcoma; Undifferentiated pleomorphic sarcoma (UPS), Malignant Fibrous Histiocytoma, High-Grade 
Spindle Cell Sarcoma; Myxofibrosarcoma; Malignant Peripheral Nerve Sheath Tumor (MPNST); Synovial 
Sarcoma) at levels similar to those found in melanoma cells (Fig1 A) by in silico with RNA-sequencing 
expression data from the TCGA database. Furthermore, using flow cytometry we observed CSPG4 expression 
on the cell surface of 15 out of 15 STS cell lines obtained from biopsies of patients affected by different 
histotypes of advanced STS (UPS n=3, GIST n=5, Liposarcoma n=4, Leiomyosarcoma n=2, MPNST n=1) and in 
the HT1080 cell line (Fibrosarcoma) from ATCC (Fig 1B).  
CSPG4 density on STS cell lines was quantified on per cell basis and found variable among STS samples (mean 
of 321±47 molecules per cell) (Fig. 1C). STS cell lines were also confirmed to express variable levels of the 
main known ligands recognized by the NKG2D CIK receptor (MIC A/B: 30% ±8; ULBP1: 1 %±0.7; ULBP2/5/6: 
71%±6; ULBP3: 25%±9). HLA class-I antigens are highly expressed by all STS cell lines tested (95%±2), along 
with varying levels of immune-checkpoints PD-L1 (32%±9) and PD-L2 (65%±6) (Suppl. Table 2). 
 
CSPG4-CAR.CIK effectively and specifically target STS in vitro. 
We explored the in vitro anti-tumor activity of CSPG4-CAR.CIK against 12 STS cell lines. In 2 cases (S1 UPS and 
S172 Leiomyosarcoma) it was possible to obtain peripheral blood from the patient from whom the STS tumor 
cell line was generated. At effector-to-target cell ratios (E:T) from 10:1 to 1:4, CSPG4-CAR.CIK revealed 
significantly superior in vitro cytotoxicity against STS (Figure 2A and Suppl. Figure 2A), as compared to that 
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reported with unmodified NTD.CIK (n=29; p<0.0001). Furthermore, the anti-tumor activity of CSPG4-CAR.CIK 
was maintained even at very low E:T ratios (1:8 to 1:64) (n=8; p<0.0001, Figure 2B).  
CSPG4-CAR.CIK antitumor activity was superior to that of control CD19-CAR.CIK (n=5, p<0.05, Figure 2C) and 
was CSPG4-specific because CSPG4-CAR.CIK did not eliminate non-expressing CSPG4 target cells (n=3, p>0.05, 
Figure 2D). Finally, at E:T ratios that mediate potent antitumor effects, CSPG4-CAR.CIK had no detectable 
activity against human keratinocytes that show low CSPG4 expression (n=5, Figure 2E). CSPG4-CAR.CIK-
mediated tumor elimination was strictly dependent on the CSPG4 expression level on tumor cells (n=7, 
p<0.05, Figure 2F).  
We also measured the antitumor activity of CSPG4-CAR.CIK cells in a STS sample expressing CSPG4, but 
lacking NKG2D ligands, and found that CAR expression per se promotes antitumor activity of redirected CIK 
independently from NKG2D CIK receptor engagement (p<0.001, Figure 2G).  
Following treatment with CSPG4-CAR.CIK, we evaluated if residual tumor cells spared by the cytotoxic effects 
of CIK may regrow. We observed significant delayed in vitro re-growth of STS cells exposed to CSPG4-CAR.CIK 
(48 hours after treatment) as compared with tumor cells exposed to unmodified NTD.CIK (n=2, p<0.05, Figure 
2H). 
A significant and superior (three-fold E:T 5:1) activity level of STS killing was displayed by CSPG4-CAR.CIK 
compared to CAR.T lymphocytes. Both effector cells were generated from PBMC collected from the same 
patient and  expressed comparable levels of CSPG4-specific CAR molecules (n=2, p<0.001, Figure 2I, Suppl. 
Figure 3A,B).   
In selected experiments, we explored the production of Th1- and Th2-type cytokines and granzyme B by 
CSPG4-CAR.CIK at baseline and following exposure to STS CSPG4-positive targets. Overall, we observed higher 
baseline productions of IFNγ, IL-6, IL1β, IL-4, IL-8, GM-CSF, TNFα, IL-10, and granzyme B by CSPG4-CAR.CIK 
that markedly increased following engagement with STS CSPG4-positive targets (n=4) (Suppl. Figure 4A). The 
highest cytokine peaks were observed for IFNγ, IL-6, IL-8, TNFα, and GM-CSF. The most differentially 
expressed cytokines by CSPG4-CAR.CIK in response to CSPG4 expressing STS as compared to NTD.CIK were: 
IFNγ (80-fold), IL1β (4.5-fold), IL-6 (1.3-fold), TNFα (7.6-fold), GM-CSF (88.5-fold), IL-10 (16-fold), IL-8 (1.3-
fold), IL-4 (7-fold) and granzyme B (20-fold). Complete cytokine values, including CAR.T lymphocytes control, 
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CSPG4-CAR.CIK effectively target STS cells in 3D spheroids. 
We developed the STS spheroid model that mimics tumor three-dimensionality (3D) and allows exploring 
CAR.CIK migration in a multidimensional structure. STS spheroids express GFP, which allows tracking their 
fate by longitudinal imaging. Spheroids were generated for three STS (S1, S5 and S172). Spheroids were co-
incubated with effector cells at E:T ratio 2:1, and loss of fluorescence over time was considered as a surrogate 
indication of tumor elimination by CSPG4-CAR.CIK (Figure 3A,B). CSPG4-CAR.CIK eliminated STS spheroids 
more effectively than unmodified NTD.CIK (n=3, p<0.0001) (Figure 4A-C).  
In selected experiments, we also used live imaging to visualize the antitumor kinetics of CSPG4-CAR.CIK 
against STS spheroids (Supplemental Video 1, 2). Furthermore, measurement of the maximum intensity 
projections of S172 and S5 spheroids after incubation with CSPG4-CAR.CIK or unmodified NTD.CIK indicated 
that CSPG4-CAR.CIK were present at a higher concentration within the STS spheroids as compared to 
unmodified NTD.CIK (n=8, p<0.05, Figure 4D-F) (Supplemental Video 3-6). Finally, in selected experiments, 
we measured the capability of CSPG4-CAR.CIK to penetrate and migrate toward STS spheroids through 
Matrigel® domes, with the intent of mimicking their dynamics through the extracellular matrix (Figure 5A). 
Microscopic inspection indicated that CSPG4-CAR.CIK readily migrated to the membrane boundary and 
penetrated the Matrigel® domes containing STS spheroids more efficiently than unmodified NTD.CIK cells 
(n=5, p<0.01, Figure 5B, C). 
 
CSPG4-CAR.CIK controlled tumor growth in vivo.  
We explored the in vivo antitumor activity of CSPG4-CAR.CIK utilizing three STS xenograft models (HT1080 
Fibrosarcoma, S172 Leiomyosarcoma, and S1 UPS) that were selected because of the different levels of 
CSPG4 expression. Upon tumor engraftment (~50 mm3) mice were treated with intravenous infusions of 
CSPG4-CAR.CIK or unmodified NTD.CIK (Figure 6A). In two models (S1 and S172) CIK and tumor cells were 
autologous, while CAR.CIK tested in the HT1080 xenograft model were allogeneic. In the S172 
leiomyosarcoma xenograft model characterized by 72% CSPG4 expression and a density of 262 
molecules/cell, autologous CSPG4-CAR.CIK, but not unmodified NTD.CIK or vehicle, caused significant delay 
in tumor growth (p<0.05) (n=6 mice/group) (Figure 6B). In the HT1080 fibrosarcoma and S1 UPS xenograft 
models showing 23% and 95% CSPG4 expression, respectively, but similar densities of target molecules (521 
and 499 mol/cell, respectively), CSPG4-CAR.CIK also delayed tumor growth as compared to controls (p<0.001 
HT1080; p<0.0001 S1) (n=3 mice/group) (Figure 6C, D). Tumor infiltration by CSPG4-CAR.CIK was confirmed 
in explanted tumors by IHC (Figure 6E). Cleaved caspase 3 levels were confirmed higher in tumors from mice 
treated with CSPG4-CAR.CIK as compared to those from NTD.CIK treated or vehicle-treated mice (Figure 6F). 
The antitumor activity of CSPG4-CAR.CIK was also verified in additional experiments in which we reduced the 
initial tumor burden (~20 mm3) for both HT1080 and S172 tumors (Suppl. Figure 5A).  In these models, CSPG4-
CAR.CIK treatment resulted in significant delay of tumor growth up to 11 days after the end of treatment as 
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compared to controls (p<0.001 HT1080; p<0.0001 S172) (Suppl. Figure 5B-E). A complete tumor regression 
was observed in 2 out of 4 mice bearing leiomyosarcoma and 1 out 5 mice bearing fibrosarcoma (HT1080).  
Of note, antitumor effects were obtained without any macroscopic evidence of toxicity. 
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STS are tumors for which the clinical impact of targeted therapies remains modest  (3). Here, we report that 
CSPG4 is a clinically relevant target in STS and that CSPG4 expression can be efficiently exploited to eliminate 
STS tumors by redirecting the specificity of CIK through CAR engineering. We generated compelling evidence 
supporting the antitumor activity of CAPG4-CAR.CIK using cell lines derived from patients who relapsed after 
conventional treatments and developing an experimental platform that includes in vitro bi-dimensional and 
three-dimensional assays along with three distinct in vivo STS xenograft models.   
The survival rate of adults and children with STS remains extremely poor even in the era of checkpoint 
inhibitors (3,50,51). The latter disappointing clinical results are likely to be caused at least in part by the 
“cold” or “immunologically-ignorant” tumor microenvironment, low neoantigen load and defects in HLA class 
I antigen-presenting machinery in STS (3,52).  
Adoptive transfer of ex vivo engineered effector T cells, and in particular CAR.T cells, providing HLA-
independent tumor recognition may offer the possibility to elicit immune responses in otherwise silent 
tumors such as STS. However, the identification of the most appropriate antigen to be recognized by CAR.T 
cells in STS remains to be defined. Here we show that CSPG4 holds critical biological features to qualify as a 
valuable target candidate in STS (38,41). Using the TCGA dataset we found that CSPG4 mRNA is highly 
expressed in STS across multiple histotypes. Furthermore, we confirmed CSPG4 protein expression on the 
cell surface of a wide array of STS cell lines spanning multiple STS histotypes and derived from patients who 
relapsed after conventional treatments. This information is critical in the clinical setting because STS are 
intrinsically highly heterogeneous especially in relapsed patients (1). Importantly, CSPG4 expression in all 
these tumor cell lines was identified by the antibody that we have used to generate the CSPG4-specific CAR 
and previously used to show the limited expression of CSPG4 in normal healthy tissues as compared to 
multiple solid tumors, despite broad CSPG4 mRNA expression in various organs (37,53). In the perspective of 
a clinical application, a systematic confirmation of CSPG4 expression by IHC in STS sections that include tumor 
microenvironment would be warranted.   
As for the majority of non-lineage restricted markers, the density of CSPG4 expression in STS cell lines was 
variable, but in general much higher of the expression detected in normal keratinocytes. We found a 
correlation between CSPG4 expression level and anti-tumor activity by CSPG4-CAR redirected CIK with 
minimal activity against normal keratinocytes. The latter finding is consistent with previous data underscoring 
the importance of antigen density to define a therapeutic window for antigens that are expressed, although 
at low levels, also by normal tissues (54,55). 
While CAR-redirected effector T cells showed potent antitumor effects in B cell malignancies, it remains to 
be defined if other cell subtypes such as NK cells, NKT cells or γδT cells may possess intrinsic biologic 
characteristics to be exploited in solid tumors to enhance the therapeutic index of engineered immune cells 
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(12). Here, rather than exploring different immune cell subsets, we propose that T cells with enhanced 
cytokine-activation during the ex vivo expansion such as CAR-engineered CIK may represent a valid cellular 
platform for the treatment of STS. Dosing and prolonged ex vivo exposure to IL-2 induces a mixed T-NK 
phenotype and function in CIK lymphocytes with variable degree of HLA-independent (NKG2D mediated) 
tumor killing ability (56). We reasoned that CAR engineered CIK would exploit dual tumor cell-killing potential 
namely antigen independent via NKG2D receptor engagement and antigen-dependent via CSPG4-CAR 
engagement. The utilization of these two mechanisms is expected to ultimately amplify the antitumor effects 
of CSPG4-CAR.CIK and potentially counteract the escape mechanisms utilized by tumor cells with low CSPG4 
expression. We found that CAR.CIK exerted potent antitumor effects against a wide array of STS, which was 
particularly evident at very low effector to target cell ratios. 
The activity of CSPG4-CAR.CIK was confirmed in three independent STS xenograft models and showed clearly 
gain of function by CIK cells expressing the CAR as compared to unmodified NTD.CIK further supporting the 
evidence that NKG2D and CAR engagement are not mutually exclusive in CAR engineered CIK. Our study using 
relatively simple 3D assays to explore the dynamic features of CAR.CIK ex vivo in a more complex structure 
compared to liquid culture also uncovered remarkable migratory and infiltrative abilities of CAR engineered 
CIK. These properties further underline the potential impact of these cells in solid tumors. It is important to 
acknowledge that clinical data indicate that CIK are more terminally differentiated as compared to activated 
and expanded T cells. As a result their longevity in vivo upon adoptive transfer may be limited (32,57). 
However, clinical data also indicate that the manufacturing of CIK both unmanipulated or CAR engineered is 
very robust. This property allows logarithmic expansion of cells in a relatively short period of time and storing 
of CIK for multiple infusions. Furthermore the initial evidence of a lower IL-1β and IL-6 production by CAR.CIK 
as compared to paired “conventional” CAR.T lymphocytes, may further support a favorable safety profile.  
Overall, our data support CSPG4 as a valuable CAR-target for STS and the use of CIK engineered to express 
the CSPG4-specific CAR for the development and implementation of a novel and effective 
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Figure 1. CSPG4 is highly expressed in multiple STS histotypes.   
CSPG4 mRNA expression in multiple STS histotypes (Leiomyosarcoma; Dedifferentiated Liposarcoma; 
Undifferentiated pleomorphic sarcoma (UPS), Malignant Fibrous Histiocytoma, High-Grade Spindle Cell 
Sarcoma; Myxofibrosarcoma; Malignant Peripheral Nerve Sheath Tumor; Synovial Sarcoma). CSPG4 
expression in STS was comparable to that observed in melanoma. RNA-sequencing expression data were 
selected and downloaded from the cBioPortal of the TCGA Pan-Cancer Collections. RSEM expression values 
were plotted after Log2 transformation with 0.5 jittering on the x-axis, using Microsoft Excel®. (A). CSPG4 
expression was confirmed in patient-derived STS cell lines of various histologic types by flow cytometry. A 
representative flow-cytometry histogram is reported for each STS. The M14 melanoma cell line that lacks 
CSPG4 expression and normal keratinocytes were used for comparison. Isotype controls are shown in grey 
(B). Grey histograms show the number of CSPG4 molecules expressed on the cell surface of various patient-
derived STS cell lines quantified as the CSPG4-specific mAb-binding capacity (sABC) on a per cell basis (C).  
Abbreviations: CSPG4, Chondroitin Sulfate proteoglycan 4; STS, Soft Tissue Sarcoma. 
Figure 2. CSPG4-CAR.CIK effectively and specifically target STS cells in vitro. 
Patient-derived CSPG4-CAR.CIK efficiently targeted STS cells in vitro when using either HLA mismatched (10 
samples) or matched CIK (2 samples). Specific cytotoxicity of CSPG4-CAR.CIK was significantly higher than 
that obtained with unmodified NTD.CIK. Tumor cell-specific cytotoxicity values from 29 experiments are 
reported (mean ± SEM) (A). CSPG4-CAR.CIK retained their antitumor activity when challenged at very low E:T 
ratios (n=8) (B). In vitro cytotoxic activity of control CD19-CAR.CIK against STS was comparable to that of 
unmodified NTD.CIK (n=5) (C). CSPG4-CAR.CIK and paired unmodified NTD.CIK showed similar cytotoxic 
activity against the M14 control cell line that lacks CSPG4 expression (n=3) (D). Both CSPG4-CAR.CIK and 
paired unmodified NTD.CIK did not lyse normal keratinocytes (n=5) (E). CSPG4-CAR.CIK exhibited more 
intense killing of STS cells with high CSPG4 expression as compared with STS cells with low CPSG4 expression 
(n=7, * P ≤ 0.05 by t-test) (F). CSPG4-CAR.CIK, but not paired unmodified NTD.CIK, retained cytotoxic activity 
against a STS sample expressing CSPG4, but lacking NKG2D ligands (S061) (n=3; two-way ANOVA and 
Bonferroni’s post-test analysis) (G). STS cell growth assessed 48 hours following in vitro treatment was 
significantly delayed in STS exposed to CSPG4-CAR.CIK, as compared with unmodified NTD.CIK. The dashed 
line represents the control parallel growth of untreated STS cells (n=2, * P ≤ 0.05 by unpaired t-test) (H). 
CSPG4-CAR.CIK displayed significant and superior STS killing activity compared to paired “non-cytokine-
induced”, but minimally activated with IL-2 (50U/ml) CAR.T expressing comparable membrane levels of 
CSPG4-specific CAR molecules (n=2, two-way ANOVA and Bonferroni’s post-test analysis) (I).  
All cytotoxicity assays were analyzed by two-way ANOVA and Bonferroni’s post-test analysis; statistical 
significance is reported as * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, and **** P ≤ 0.0001; “n” refers to the number 
of separate experiments.  
 
Abbreviations: CIK, Cytokine Induced Killer cells; CSPG4, Chondroitin Sulfate proteoglycan 4; CAR, Chimeric 
Antigen Receptor; NTD, Not Transduced; STS, Soft Tissue Sarcoma. 
Figure 3. CSPG4-CAR.CIK effectively target STS cells in 3D spheroids. 
Schematic showing the 3D assay to test the cytotoxic activity of CSPG4-CAR.CIK against GFP-expressing STS 
spheroids (green) (A). CSPG4-CAR.CIK showed superior tumor elimination, as compared to paired unmodified 
NTD.CIK. Shown are representative microscope fluorescence images and surface plot images of GFP-
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expressing STS spheroids (green) treated with CSPG4-CAR.CIK (up to 72 hours) and control CIK.  
Magnification: 10X; Scale bars: 100 μm (B).  
Abbreviations: CIK: Cytokine Induced Killer cells; CSPG4: Chondroitin Sulfate proteoglycan 4; CAR: Chimeric 
Antigen Receptor; NTD: Not Transduced; STS: Soft Tissue Sarcoma; GFP: Green Fluorescent Protein. 
Figure 4. CSPG4-CAR.CIK infiltrate 3D STS spheroids. 
CSPG4-CAR.CIK displayed cytolytic activity against 3D STS spheroids. Tumor cell elimination mediated by 
CSPG4-CAR.CIK was quantified by measuring GFP fluorescence loss overtime of S1 (A), S5 (B) and S172 (C) 
spheroids (pixel) by fluorescence microscopy. Values are reported as means (±SEM) from three independent 
wells (2:1 E:T ratio). Results were analyzed by two-way ANOVA and Bonferroni’s post-test analysis; statistical 
significance is reported as * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, and **** P ≤ 0.0001. Representative 
maximum intensity projections of confocal microscopy images for S5 (D) and S172 (E) spheroids (green) 
treated with unmodified PKH26-stained (red) NTD.CIK and CSPG4-CAR.CIK (2:1 E:T ratio). Confocal 
microscopy images taken 16 hours after co-incubating CIK and STS spheroids. 20X magnification and scale 
bars: 100 μm are shown. (F) CSPG4-CAR.CIK displayed superior infiltration within the STS spheroids (green) 
as compared with paired unmodified NTD.CIK (n=8, P≤0.05 by paired t-test). CSPG4-CAR.CIK density was 
determined as red fluorescent PKH26 area (μm2).  
Abbreviations: CIK: Cytokine Induced Killer cells; CSPG4: Chondroitin Sulfate Proteoglycan 4; CAR: Chimeric 
Antigen Receptor; NTD: Not Transduced; STS: Soft Tissue Sarcoma; GFP: Green Fluorescent Protein. 
Figure 5. CSPG4-CAR.CIK penetrate Matrigel matrix toward the STS spheroids. 
Schematic showing the Matrigel® based penetration assay. STS spheroids were embedded into Matrigel® 
domes and co-cultured with either PKH26-stained CSPG4-CAR.CIK or unmodified NTD.CIK at E:T ratios 10:1. 
Empty domes served as controls. Fluorescence microscope images were acquired at day 5 of co-culture (A). 
Representative imagines of CSPG4-CAR.CIK and unmodified NTD.CIK empty or STS spheroids embedded in 
Matrigel® domes are displayed. Dashed lines represent Matrigel® boundaries. Top panel includes bright field 
microscope images; bottom panel includes fluorescent images. Magnification: 4X; Scale bars: 100 μm (B). 
Summary showing that CSPG4-CAR.CIK displayed superior ability in penetrating Matrigel® domes as 
compared to paired NTD.CIK (n=5, P≤0.01 by paired t-test). CSPG4-CAR.CIK density was defined as the 
fluorescent PKH26 area (μm2) (C).  
Abbreviations: CIK: Cytokine Induced Killer cells; CSPG4: Chondroitin Sulfate Proteoglycan 4; CAR: Chimeric 
Antigen Receptor; NTD: Not Transduced; STS: Soft Tissue Sarcoma. 
Figure 6. CSPG4-CAR.CIK are active against STS in xenograft models. 
Schematic representation of the STS xenografts and treatment with CSPG4-CAR.CIK (red arrows) and NTD.CIK 
(blue arrows). Vehicle-treated mice were infused with PBS (grey arrows). CIK were infused intravenously 
(1x106 cells/infusion) twice a week for 2 weeks (A). Autologous CSPG4-CAR.CIK caused a significant delay of 
the growth of the S172 leiomyosarcoma (CSPG4=72% and CSPG4 density=262 molecule/cell) as compared to 
unmodified NTD.CIK or vehicle-treated mice (n=6; p<0.05) (B). Autologous CSPG4-CAR.CIK caused a 
significant delay of the growth of the HT1080 fibrosarcoma (CSPG4=23% and CSPG4 density=521 
molecule/cell) as compared to unmodified NTD.CIK or vehicle-treated mice (n=3, p<0.001). (C). Autologous 
CSPG4-CAR.CIK effectively delayed the growth of S1 UPS (CSPG4=95% and CSPG4 density=499 molecule/cell) 
as compared with controls (n=3, p<0.0001). All results were analyzed by two-way ANOVA and the Bonferroni 
post-test; statistical significance is reported as * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, and **** P ≤ 0.0001. 
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(D). Tumor-homing of CSPG4-CAR.CIK and unmodified NTD.CIK was confirmed by IHC in explanted tumors 
using an anti-human CD3 antibody staining. Magnification: 40X; Scale bars: 50 μm (E). Apoptotic tumor cells 
were visualized by detecting cleaved caspase 3 by IHC in explanted tumors (F). 
Abbreviations: CIK: Cytokine Induced Killer cells; CSPG4: Chondroitin Sulfate Proteoglycan 4; CAR: Chimeric 
Antigen Receptor; NTD: Not Transduced; NOD/SCID: Non-obese diabetic/severe combined 
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Figure 2. CSPG4-CAR.CIK effectively and specifically target STS cells in vitro. 
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Figure 3. CSPG4-CAR.CIK effectively target STS cells in 3D spheroids. 
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Figure 6.  CSPG4-CAR.CIK are active against STS in xenograft models. 
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